Angiopoietin-like proteins 3, 4 and 8: Regulating lipid metabolism and providing new hope for metabolic syndrome

Journal of Drug Targeting

Volumn 22, Issue 8, 2014, Pages 679-687

  Li, Yunchao ^a   Teng, Chunbo ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Angiopoietin like protein; Lipoprotein lipase; Metabolic syndrome; Target therapy; Triglyceride

Indexed keywords

ANGIOPOIETIN; ANGPTL3 PROTEIN, HUMAN; ANGPTL4 PROTEIN, HUMAN; LIPASIN PROTEIN, HUMAN; PEPTIDE HORMONE;

GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; PHYSIOLOGY;

ANGIOPOIETINS; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; PEPTIDE HORMONES;

EID: 84905815417     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.928715     Document Type: Review

References (70)

1. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocytederived bioactive substances. Ann N Y Acad Sci 1999;892: 146-54.
2. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104: 531-43.
3. Billington CJ, Epstein LH, Goodwin NJ, et al. Overweight, obesity, and health risk. Arch Intern Med 2000;160: 898-904.
4. Hu G, Qiao Q, Tuomilehto J. The metabolic syndrome and cardiovascular risk. Curr Diabetes Rev 2005;1: 137-43.
5. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83: 25F-9F.
6. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112: 2735-52.
7. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005;11: 473-9.
8. Camenisch G, Pisabarro MT, Sherman D, et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem 2002;277: 17281-90.
9. Zhang CC, Kaba M, Ge G, et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006;12: 240-5.
10. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta 2012;1821: 782-9.
11. Kersten S. Regulation of lipid metabolism via angiopoietin-like proteins. Biochem Soc Trans 2005;33: 1059-62.
12. Galaup A, Cazes A, Le Jan S, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006;103: 18721-6.
13. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med 2008;18: 6-14.
14. Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab 2009;10: 178-88.
15. Zhu P, Goh YY, Chin HF, et al. Angiopoietin-like 4: a decade of research. Biosci Rep 2012;32: 211-19.
16. Kim I, Moon SO, Koh KN, et al. Molecular cloning, expression, and characterization of angiopoietin-related protein. Angiopoietinrelated protein induces endothelial cell sprouting. J Biol Chem 1999;274: 26523-8.
17. Kim I, Kim HG, Kim H, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000;346: 603-10.
18. Dhanabal M, Jeffers M, La Rochelle WJ, Lichenstein HS. Angioarrestin: a unique angiopoietin-related protein with antiangiogenic properties. Biochem Biophys Res Commun 2005;333: 308-15.
19. Smagur A, Szary J, Szala S. Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours. Acta Biochim Pol 2005;52: 875-9.
20. Kuo TC, Tan CT, Chang YW, et al. Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. J Clin Invest 2013; 123: 1082-95.
21. Aoi J, Endo M, Kadomatsu T, et al. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res 2011;71: 7502-12.
22. Tan MJ, Teo Z, Sng MK, et al. Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res 2012;10: 677-88.
23. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009;119: 70-9.
24. Comes N, Buie LK, Borrás T. Evidence for a role of angiopoietin-like7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Genes Cells 2011; 16: 243-59.
25. Fu Z, Yao F, Abou-Samra AB, Zhang R. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun, 2013;430: 1126-31.
26. Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 2012;424: 786-92.
27. Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA 2012; 109: 19751-6.
28. Wang Y, Quagliarini F, Gusarova V, et al. Mice lacking ANGPTL8 (betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA 2013;110: 16109-14.
29. Lee EC, Desai U, Gololobov G, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 2009;284: 13735-45.
30. Koishi R, Ando Y, Ono M, et al. ANGPTL3 regulates lipid metabolism in mice. Nat Genet 2002;30: 151-7.
31. Ono M, Shimizugawa T, Shimamura M, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem 2003;278: 41804-9.
32. Köster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: regulation of triglyceride metabolism. Endocrinology 2005;146: 4943-50.
33. Blasius AL, Brandl K, Crozat K, et al. Mice with mutations of Dock7 have generalized hypopigmentation and white-spotting but show normal neurological function. Proc Natl Acad Sci USA 2009; 106: 2706-11.
34. Shaheen R, Faqeih E, Sunker A, et al. Recessive mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal actin cytoskeleton organization and Adams-Oliver syndrome. Am J Hum Genet 2011;89: 328-33.
35. Zhang R, Abou-Samra AB. Emerging roles of lipasin as a critical lipid regulator. Biochem Biophys Res Commun 2013;432: 401-5.
36. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 2013;153: 747-58.
37. Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 2012;303: E334-51.
38. Pelham HR. The retention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci 1990;15: 483-6.
39. Romeo S, Pennacchio LA, Fu Y, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007;39: 513-16.
40. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010;363: 2220-7.
41. Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of antiangiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci USA 2007;104: 11766-71.
42. Ge H, Cha JY, Gopal H, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 2005;46: 1484-90.
43. Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim 2006;55: 27-34.
44. Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem 2009;284: 1419-24.
45. Yin W, Romeo S, Chang S, et al. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem 2009;284: 13213-22.
46. Jin W, Wang X, Millar JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007;6: 129-36.
47. Schjoldager KT, Vester-Christensen MB, Bennett EP, et al. O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of polypeptide Gal NActransferase-2 in regulation of concentrations of plasma lipids. J Biol Chem 2010;285: 36293-303.
48. Inaba T, Matsuda M, Shimamura M, et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem 2003;278: 21344-51.
49. Kaplan R, Zhang T, Hernandez M, et al. Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res 2003;44: 136-43.
50. Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ. Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol 2006;256: 23-33.
51. Inukai K, Nakashima Y, Watanabe M, et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun 2004;317: 1075-9.
52. Shimamura M, Matsuda M, Ando Y, et al. Leptin and insulin downregulate angiopoietin-like protein 3, a plasma triglyceride-increasing factor. Biochem Biophys Res Commun 2004;322: 1080-5.
53. Fugier C, Tousaint JJ, Prieur X, et al. The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone. J Biol Chem 2006;281: 11553-9.
54. Lu B, Moser A, Shigenaga JK, et al. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun 2010;391: 1737-41.
55. Lei X, Shi F, Basu D, et al. Proteolytic processing of angiopoietinlike protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem 2011;286: 15747-56.
56. Ge H, Yang G, Yu X, et al. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. J Lipid Res 2004;45: 2071-9.
57. Mandard S, Zandbergen F, Tan NS, et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 2004;279: 34411-20.
58. Heinäniemi M, Uski JO, Degenhardt T, Carlberg C. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol 2007;8: R147.
59. Kaddatz K, Adhikary T, Finkernagel F, et al. Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription. J Biol Chem 2010;285: 29469-79.
60. Stockert J, Adhikary T, Kaddatz K, et al. Reverse crosstalk of TGFβ and PPAR β/δ signaling identified by transcriptional profiling. Nucleic Acids Res 2011;39: 119-31.
61. Yamada T, Ozaki N, Kato Y, et al. Insulin downregulates angiopoietin-like protein 4 mRNA in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006;347: 1138-44.
62. Koliwad SK, Kuo T, Shipp LE, et al. Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J Biol Chem 2009;284: 25593-601.
63. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77: 289-312.
64. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism - novel insights from genome-wide studies. FEBS Lett 2010;584: 3242-9.
65. McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51: 7-18.
66. Unger RH. Lopotoxic disease. Annu Rev Med 2002;53: 319-36.
67. Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005;102: 6086-91.
68. Wang Y, Lam KS, Lam JB, et al. Overexpression of angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice. Mol Endocrinol 2007;21: 972-86.
69. Jonker JT, Smit JW, Hammer S, et al. Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am J Clin Nutr 2013;97: 255-60.
70. Zhang Y, Li R, Meng Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014;63: 514-25.